DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Information source: Clinical Alliance for Research & Education - Infectious Diseases, LLC.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections; Lipodystrophy

Intervention: atazanavir (Reyataz) (Drug); ritonavir (Norvir) (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Clinical Alliance for Research & Education - Infectious Diseases, LLC.

Official(s) and/or principal investigator(s):
Richard A Elion, MD, Principal Investigator, Affiliation: Whitman-Walker Clinic

Overall contact:
Richard A. Elion, MD, Email: drrelion@aol.com

Summary

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Clinical Details

Official title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Na´ve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Detailed description: Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir

(Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen

- Viral load <50 copies/ml

Exclusion Criteria:

- Viral load >50 copies/ml

- Having taken more than one antiretroviral regimen

Locations and Contacts

Richard A. Elion, MD, Email: drrelion@aol.com

Whitman-Walker Clinic, Washington, District of Columbia, United States; Recruiting
Richard Elion, MD, Email: drrelion@aol.com
Richard A Elion, MD, Principal Investigator
Additional Information

Starting date: August 2006
Last updated: October 30, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017